Antibody ID	ANI0LNFRO
Antibody Name	huAb3v2.6
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG1-kappa
Antigen Name	CD276 antigen (CD276)					Antigen Info

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	43.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.40 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	47.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	50.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	60.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	63.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q14Dx3/IP).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 1 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 10 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	99.00%	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of huAb13vl as CZ or TX conjugates as purified DAR2 (E2)conjugates were characterized in enograft models of non-small cell lung cancer of human origin. The dose was ADC 3 mg/kg (Q4Dx6/IP) plus Docetaxel 7.5 mg/kg (Q14Dx3/IV).
In Vivo Model	NCI-H1650 CDX model
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.24 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.47 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	93.00%	Positive CD276 expression (CD276 +++/++)
Method Description	Humanized anti-B7-H3 antibodies huAb13v1, huAb3v2.5 and huAb3v2.6 were selected to beconjugated with several Bcl-xL inhibitor payloads and were evaluated in xenograft models of small cell lung cancer (H146). The dose was 6 mg/kg/IP/QDx1.
In Vivo Model	H146 CDX model
In Vitro Model	Small cell carcinoma	NCI-H146 cells		CVCL_1473

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.70 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the H847 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung small cell carcinoma	NCI-H847 cells		CVCL_1596
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.40 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.52 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.68 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.71 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.72 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.79 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.85 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.01 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.11 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	1.35 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.07 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Effective Concentration (EC50)	5.52 nM	Positive CD276 expression (CD276 +++/++)
Method Description	The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the NCI-H1650 non-small cell lung cancer cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483

Ref 1	Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.